ClinicalTrials.gg
RecruitingNCT06116331Updated Nov 3, 2023

The Mind-Body IBD Study: Understanding the Mind-body Connection in IBD

An observational study in Inflammatory Bowel Diseases, Crohn Disease and Ulcerative Colitis, sponsored by King's College London. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-03.

Sponsored by King's College London · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
170
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 112 studies in Inflammatory Bowel Diseases with a site in United Kingdom — 20 open to participants now, 28 under way, 6 of them phase 3. Inflammatory Bowel Diseases · United Kingdom.

Planned enrollment
25th of 42
170 · median 215
Started
2023
with 4 others
Observational
42 of 112
9 open now
Primary completion
2024-12
later than 5 of 27 live
Registered
98th of 112
by date
Lead sponsor
5 of 112
King's College London

Among the 112 studies in Inflammatory Bowel Diseases with a site in United Kingdom, this one is the 25th largest by planned enrollment of the 42 observational ones that give a count, is one of 5 that started in 2023, is one of 42 observational ones, reaches primary completion later than 5 of the 27 other live ones, and was the 98th registered.

Inflammatory Bowel Diseases

1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

20 of the 112 studies in Inflammatory Bowel Diseases with a site in United Kingdom are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 112 studies in Inflammatory Bowel Diseases with a site in United Kingdom, or all of them as a file.
02

Study summary

An aspect of IBD care that is often overlooked is mental health treatment. Common mental health problems, such as anxiety and depression are very common in IBD, with a meta-analysis estimating prevalence as high as 25.2% for depression and 32.1% for anxiety. The prevalence of anxiety and depression increases when individuals with active disease are considered, with rates as high as 57.6% for anxiety and 38.9% for depression. Comorbid depression and anxiety in IBD is associated with greater symptom severity, even when statistically controlling for disease activity; more frequent and expensive emergency department visits and inpatient stays, higher costs relating to IBD-related surgery, medication and personal expenditure; noncompliance with medical treatment and finally, increased likelihood of experiencing flares.

However, very few studies attempt to unpick the precise mechanism of these bidirectional relationships.

Indeed, depression and anxiety may have direct effects on physical health through inflammatory or psychoneuroimmunological pathways. Very few studies investigate the longitudinal brain-gut relationship with regards to objective measures of inflammation. Additionally, the indirect effects of mental health are often overlooked. Depression and anxiety are routinely associated with health behaviours, such as diet, physical activity, sleep, and tobacco/alcohol use.These health behaviours are important factors, given their impact on physical health outcomes. Therefore, a thorough investigation is required to ascertain the precise mechanisms that underpin the bidirectional relationship between depression/anxiety and inflammation/physical health, as this will enable practitioners and researchers to establish non-invasive, behavioural treatment targets for this patient group.

AIM The broad aim of this project is to explore whether anxiety/depression has a direct or indirect (via health behaviours) on i) inflammation levels ii) clinical activity and iii) healthcare usage at follow-up, in a population of IBD patients. A secondary aim of the project will be to explore whether changes in disease activity, as measured by self-report measures and faecal calprotectin, explains changes in anxiety and depression symptoms at follow up.

Read the detailed description

Participants will be asked to answer online questionnaires at 3 time points, 6 months apart. They will also be asked to do an at-home stool sample test at the first two time points.

03

Conditions studied

  • Inflammatory Bowel Diseases
  • Crohn Disease
  • Ulcerative Colitis
  • Crohn Colitis

Keywords

  • mental health
  • depression
  • anxiety
  • psychology
  • health
  • exercise
  • stress
  • diet
  • sleep
  • adherence
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults with IBD in the UK, who have experienced a flare within the last 2 years.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Self-reported diagnosis of IBD (pseudo-confirmed with participant's self-reported IBD medication or medication history)
  2. Willing and able to give and participate in the study
  3. Aged 18 and over
  4. Sufficient command of written and spoken English to understand study procedures and documents, and complete self-report questionnaires
  5. UK resident (GP registered)
  6. Email address, telephone number and postal address to enable all study procedures
  7. Experience at least one flare (requiring medical escalation or medication change) within the last two years

Exclusion criteria

Exclusion Criteria:

  1. Under 18 years
  2. Lives outside of the UK
  3. Insufficient command of English to understand study documents and procedures
  4. Not able to give Regular use of non-steroidal anti-inflammatory drugs (NSAIDs) in the last two weeks.
  5. People with a cancer diagnosis
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
170 participants (estimated)
Patient registry
No

Groups and cohorts

  • Participants

    Participants will complete 3 online questionnaires at 6 month intervals. At the first two time points they will also be asked to submit 2 at home stool sample tests, to assess fecal calprotectin.

    Other: Data collection

Interventions

  • OtherData collection

    Participants will answer questionnaires and submit stool samples.

06

What researchers measure

Primary outcomes

  1. Psychological distress: Patient Health Questionnaire Anxiety and Depression Scale (PHQ-ADS)

    The PHQ-ADS is a composite measure of the Generalised Anxiety Disorder questionnaire (GAD-7) and the Patient Health Questionnaire (PHQ-9). Min score = 0, Max score = 48, with higher scores indicating higher levels of distress.

    Time frame: Month 0, Month 6, Month 12

  2. Depression: Patient Health Questionnaire - (PHQ-9)

    Depression. Min score = 0, Max score = 27, with higher scores indicating greater depression.

    Time frame: Month 0, Month 6, Month 12

  3. Anxiety: Generalised Anxiety Disorder scale (GAD-7)

    Anxiety. Min score = 0, Max score = 21, with higher scores indicating greater anxiety

    Time frame: Month 0, Month 6, Month 12

  4. Fecal Calprotectin

    Measure of intestinal inflammation, higher levels indicate greater inflammation.

    Time frame: Month 0, Month 6

  5. Health service use

    4 service use items (GP, psychologist, emergency care, secondary care service) from the client service receipt inventory (CSRI) will be used. Frequency and duration of particular services will be recorded, from which a total time will be calculated. There is no maximum value. Higher scores indicate more health service time used.

    Time frame: Month 0, Month 6, Month 12

  6. IBD activity

    For Crohn's Disease patients: The Patient-Reported Outcomes for the Assessment of Crohn's Disease Activity (PRO-CD). The scale contains two sub-scales: 1) bowel signs and symptoms, 2) functional symptoms. Each scale is scored separately. There is no total score for the PRO-CD. The first sub-scale starts at 0 and has no maximum value, with greater scores indicating greater bowel signs/symptoms. The second subscale ranges from 0-21, with higher scores indicating greater functional symptoms. For Ulcerative Colitis / unclassified patients: The Patient-Reported Outcomes for Assessment of Ulcerative Colitis (PRO-UC). The scale has 9-items and includes two scales: 1) Bowel signs/symptoms and 2) functional symptoms. The first sub-scale starts at 0 and has no maximum value, with greater scores indicating greater bowel signs/symptoms. The second subscale ranges from 0-21, with higher scores indicating greater functional symptoms.

    Time frame: Month 0, Month 6, Month 12

Secondary outcomes

  1. Body Mass Index

    Weight (in kg) and Height (in m) will be combined to calculate BMI (weight in kg / (height in m)\^2

    Time frame: Month 0, Month 6, Month 12

  2. Smoking status

    Current smoking status, including amount of cigarettes consumed per day.

    Time frame: Month 0, Month 6, Month 12

  3. Alcohol Consumption

    Number of units drunk in the past week.

    Time frame: Month 0, Month 6, Month 12

  4. Physical activity: International Physical Activity Questionnaire

    Physical activity. There are three subscales (vigorous activity, moderate activity and lower-level activity). Scores will be in minutes. Higher scores will indicate more physical activity performed.

    Time frame: Month 0, Month 6, Month 12

  5. IBD medication

    Current medication and dose.

    Time frame: Month 0, Month 6, Month 12

  6. IBD flares

    Frequency and severity (4-point scale) of IBD flares (in last 6 months)

    Time frame: Month 0, Month 6, Month 12

  7. Sleep - the Pittsburgh Sleep Quality Index (PSQI)

    Sleep quality in the last month. Min=0, max=21, with higher scores indicating worse sleep quality.

    Time frame: Month 0, Month 6, Month 12

  8. Diet - Healthy Eating Assessment

    8-item simplified food frequency questionnaire designed for use in primary care settings. The tool will be adapted so that each item is score 1-5. Mix=8, max=40, with higher scores indicating better diet quality.

    Time frame: Month 0, Month 6, Month 12

  9. IBD quality of life - short Inflammatory Bowel Disease Questionnaire (sIBDQ)

    The sIBDQ is a ten-item questionnaire that covers four domains: bowel symptoms, systemic symptoms, emotional health, and social functions. Min=10, max=70, with a lower score indicating lower quality of life.

    Time frame: Month 0, Month 6, Month 12

  10. Medication Adherence - Medication Adherence Report Scale (MARS)

    5-item scale on a 5-point scale.Mix=0, Max=20, with higher scores indicating better adherence.

    Time frame: Month 0, Month 6, Month 12

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Dec 2024, 20 months after the start.

Of 244 non-industry observational studies under Inflammatory Bowel Diseases, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 132. This study's planned 20 months is below that.

Counting every sponsor, half of 281 studies reached it within 36 months; a quarter within 20 and three quarters within 122.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2023
First posted
Nov 3, 2023
StartActual
Apr 1, 2023
Primary completionEst.
Dec 1, 2024
CompletionEst.
Dec 31, 2024
Last update
Nov 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06116331
Collaborators
Medical Research Council
Responsible party
Sponsor
First posted
Nov 3, 2023
Start date
Apr 1, 2023
Primary completion
Dec 1, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Nov 3, 2023

Study contacts

Natasha Seaton, MSc
Contact
natasha.seaton@kcl.ac.uk
0207 188 1189
Natasha Seaton
Contact
mindbody-ibd@kcl.ac.uk
0207 188 1189
Rona Moss-Morris, PhD
principal investigator · King's College London

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion